“…Of these articles, 12 were on non-small cell lung cancer (NSCLC) (49.48% of patients),2,3,16,18,19,21,22,24,26,27,35,38 two on malignant glioma (5.90% of patients),23,34 two on metastatic colorectal cancer (CRC) (7.63% of patients),31,36 two on gastrointestinal stromal tumor (GIST) (7.28% of patients),29,30 two on metastatic renal cell carcinoma (RCC) (9.60% of patients),25,37 and five on other solid tumors (metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic melanoma, biliary tract cancer, and mixed kinds of tumors; 20.12% of patients) 17,20,28,32,33. Meanwhile, all of these articles coped with molecularly targeted therapy: six with erlotinib,3,16,21,22,24,27 six with bevacizumab,23,26,28,31,34,36 four with gefitinib,2,19,35,38 three with imatinib,17,29,32 two with sunitinib,25,30 one with cetuximab,33 and three with mixed kinds of molecularly targeted agents 18,20,37. PET-CT/PET was performed pretherapy and posttreatment.…”